ImmunoGen, Inc. - IMGN STOCK NEWS

ImmunoGen Inc. (NASDAQ: IMGN) has appointed Mimi Huizinga, MD, MPH, FACP as Senior Vice President and Head of Medical Affairs. This new role emphasizes the growing importance of Medical Affairs alongside R&D and Commercial operations, particularly as the company prepares to launch its lead candidate, mirvetuximab soravtansine, for ovarian cancer. Dr. Huizinga joins from Rafael Holdings, bringing extensive experience in oncology and medical affairs, previously holding significant roles at Novartis and Premier, Inc.

ImmunoGen Inc. (Nasdaq: IMGN) announced the granting of a non-qualified stock option award for 16,800 shares as part of its Inducement Equity Incentive Plan to a new employee on December 31, 2021. The option has an exercise price of $7.42, aligning with the stock's closing price on that date. The options will vest over four years, with 25% vesting after one year and the remainder vesting quarterly, contingent on continued employment. This plan is designed to attract new talent to ImmunoGen.

ImmunoGen, a leader in antibody-drug conjugates for cancer treatment, announced that CEO Mark Enyedy will present at the 40th Annual J.P. Morgan Virtual Healthcare Conference. The presentation is set for 9:00 AM ET on January 12, 2022, followed by a Q&A session at 9:20 AM ET. Investors and interested parties can access a live webcast of the event on the company’s website, with a replay available later. ImmunoGen focuses on developing targeted therapies to improve cancer patient outcomes, promoting a mission to 'TARGET A BETTER NOW.'

ImmunoGen, Inc. (NASDAQ: IMGN) presented promising initial safety and efficacy data for its candidate IMGN632 at the 63rd ASH Annual Meeting. The Phase 1b/2 study showcased a 48% objective response rate in patients with relapsed/refractory acute myeloid leukemia (AML) and a 30% complete remission rate. A manageable safety profile was observed, with no serious adverse events such as tumor lysis syndrome. Additionally, data presented for IMGN632 in blastic plasmacytoid dendritic cell neoplasm (BPDCN) patients indicated clinical complete responses, supporting ongoing patient enrollment for pivotal studies.

ImmunoGen, a leader in antibody-drug conjugates for cancer treatment, has successfully completed a public offering of 17,486,364 common shares, raising approximately $295.7 million. The shares were sold at $6.60 each, with additional pre-funded warrants also included. The funds will support commercialization, clinical trials, drug production, and working capital. Jefferies, Cowen, and Guggenheim Securities managed the offering. This is part of ImmunoGen's ongoing commitment to develop advanced therapies aimed at improving cancer patient outcomes.

ImmunoGen Inc. (NASDAQ: IMGN) announced a public offering of 11,636,364 shares of common stock priced at $6.60 per share, with pre-funded warrants available to certain investors. The offering, expected to close on or around December 6, 2021, aims to raise gross proceeds of approximately $257.1 million. The proceeds will support operational activities like commercialization, clinical trials, drug supply, and working capital. Jefferies, Cowen, and Guggenheim Securities are joint book-running managers for the offering.

ImmunoGen Inc. (NASDAQ: IMGN) has announced plans for an underwritten public offering of $175 million in shares of common stock, with an option for underwriters to purchase additional shares. The proceeds will support operations including commercialization and clinical trials. The offering is subject to market conditions and is registered with the SEC. Jefferies, Cowen, and Guggenheim Securities are the joint book-running managers. The final terms of the offering remain uncertain, as completion depends on market conditions.

ImmunoGen announced positive results from the pivotal SORAYA trial for mirvetuximab in patients with FRα-high platinum-resistant ovarian cancer. The trial met its primary endpoint with a confirmed objective response rate (ORR) of 32.4%. The median duration of response was reported at 5.9 months. The treatment demonstrated a favorable tolerability profile, with common adverse events reported. A BLA submission to the FDA is expected in Q1 2022, marking a significant step towards potential approval.

On November 22, 2021, ImmunoGen Inc. granted non-qualified stock options to purchase 327,700 shares to ten new employees under its Inducement Equity Incentive Plan. The options have an exercise price of $5.06 per share, equal to the closing price on that day. These stock options are intended as an inducement for employment and will vest over four years. ImmunoGen specializes in antibody-drug conjugates aimed at improving cancer treatment outcomes.